106 related articles for article (PubMed ID: 2477047)
1. Misteltoe (Iscador) therapy in stage IV renal adenocarcinoma. A phase II study in patients with measurable lung metastases.
Kjaer M
Acta Oncol; 1989; 28(4):489-94. PubMed ID: 2477047
[TBL] [Abstract][Full Text] [Related]
2. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador.
Grossarth-Maticek R; Ziegler R
Arzneimittelforschung; 2007; 57(10):665-78. PubMed ID: 18074761
[TBL] [Abstract][Full Text] [Related]
3. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis.
Grossarth-Maticek R; Ziegler R
Eur J Med Res; 2006 Nov; 11(11):485-95. PubMed ID: 17182361
[TBL] [Abstract][Full Text] [Related]
4. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study.
Bar-Sela G; Wollner M; Hammer L; Agbarya A; Dudnik E; Haim N
Eur J Cancer; 2013 Mar; 49(5):1058-64. PubMed ID: 23218588
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW
Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151
[TBL] [Abstract][Full Text] [Related]
6. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador).
Grossarth-Maticek R; Ziegler R
Forsch Komplementmed; 2006 Oct; 13(5):285-92. PubMed ID: 17057389
[TBL] [Abstract][Full Text] [Related]
7. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador).
Grossarth-Maticek R; Ziegler R
Forsch Komplementmed; 2007 Jun; 14(3):140-7. PubMed ID: 17596694
[TBL] [Abstract][Full Text] [Related]
8. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador).
Grossarth-Maticek R; Ziegler R
Eur J Med Res; 2008 Mar; 13(3):107-20. PubMed ID: 18499556
[TBL] [Abstract][Full Text] [Related]
9. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study.
Grossarth-Maticek R; Kiene H; Baumgartner SM; Ziegler R
Altern Ther Health Med; 2001; 7(3):57-66, 68-72, 74-6 passim. PubMed ID: 11347286
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of lung metastasis by adoptive immunotherapy using Iscador.
Antony S; Kuttan R; Kuttan G
Immunol Invest; 1999 Jan; 28(1):1-8. PubMed ID: 10073677
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer.
Laohavinij S; Maoleekoonpairoj S; Cheirsilpa A; Maneechavakajorn J; Sirachainant E; Arpornvivat W; Jaisathaporn K; Ratanatharathorn V
Lung Cancer; 1999 Dec; 26(3):175-85. PubMed ID: 10598928
[TBL] [Abstract][Full Text] [Related]
12. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
[TBL] [Abstract][Full Text] [Related]
13. Anticarcinogenic and antimetastatic activity of Iscador.
Kuttan G; Menon LG; Antony S; Kuttan R
Anticancer Drugs; 1997 Apr; 8 Suppl 1():S15-6. PubMed ID: 9179361
[TBL] [Abstract][Full Text] [Related]
14. Role of natural killer cells in iscador mediated inhibition of metastasis by adoptive immunotherapy.
Antony S; Kuttan R; Kuttan G
Immunol Invest; 2000 Aug; 29(3):219-31. PubMed ID: 10933606
[TBL] [Abstract][Full Text] [Related]
15. High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase II study.
Kjaer M; Frederiksen PL
Cancer Treat Rep; 1986 Mar; 70(3):431-2. PubMed ID: 2937534
[No Abstract] [Full Text] [Related]
16. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
Scott LC; Yao JC; Benson AB; Thomas AL; Falk S; Mena RR; Picus J; Wright J; Mulcahy MF; Ajani JA; Evans TR
Cancer Chemother Pharmacol; 2009 Jan; 63(2):363-70. PubMed ID: 18398613
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
[TBL] [Abstract][Full Text] [Related]
19. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
Fuchs CS; Moore MR; Harker G; Villa L; Rinaldi D; Hecht JR
J Clin Oncol; 2003 Mar; 21(5):807-14. PubMed ID: 12610178
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Bathe OF; Dowden S; Sutherland F; Dixon E; Butts C; Bigam D; Walley B; Ruether D; Ernst S
BMC Cancer; 2004 Jul; 4():32. PubMed ID: 15245580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]